EU set to speed up switch to bioeconomy by new action plan

Six years after the European Commission created the world’s first bioeconomy strategy and action plan, it presented a new action plan aimed at moving faster towards a climate-neutral, sustainable, biobased industry.  

Read more

Bacterial antigen mimicry drives MS

T cells target a bacterial variant of a human enzyme promoting autoimmune diseases such as Multiple Sclerosis (MS).

Read more

Sitryx Therapeutics bags $30m in Series A Financing

Oxford-based immunoncology player Sitryx Therapeutics Ltd. (Oxford, U.K.) has bagged $30m in a Series A financing round led by SV Health Investors and new investor Sofinnova Partners. Longwood Fund and GlaxoSmithKline plc participated in this financing.

Read more

Orchard plans to raise US$172m in ADS

British gene therapy developer Orchard Therapeutics will go IPO on Nasdaq, according to SEC filings. The company plans to raise $172.5m as ADS in an IPO underwritten by J.P. Morgan, Goldman Sachs, Cowen and Wedbush PacGrow to balance its costs, which rose from US$13m to US$138m this year. Financial markets are expected to react positively.

Read more

Sphingotec raises €20m in growth equity financing

Diagnostics company sphingotec GmbH successfully closed a €20m growth equity financing round led by international specialist investors HBM Healthcare Investments, HBM BioCapital II LP (HBM) and Wellington Partners.

Read more

Sanofi and Evotec launch drug discovery PPP

Evotec and Sanofi have launched a Public Private Partnership (PPP) aimed at partnering with academic groups in early stage drug discovery across multiple therapeutic areas. 

Read more

Roche providing improved anti-Her2 bispecific antibody

Researchers at at VHIO in Barcelona, Spain, and Roche in Schlieren have presented a bi-specific antibody that prevents the side effects of HER2-targeting compounds.

Read more

Forbion closes Life Sciences VC Fund at €360m

Life Sciences venture capitalist Forbion has closed its  new flagship fund, Forbion IV, at €360m, €90m above its original target of €250m.

Read more

BIOSPAIN expanding

Matured, diversified and willing to expand – this is how the Spanish biotech sector presented itself during BIOSPAIN 2018 in Seville. Andalusia has launched the first bioeconomy policy strategy in Spain. 

Read more

Minoryx bags €21.3m Series B financing

Barcelona-based Minoryx Therapeutics announced during BIOSPAIN 2018 it has raised another €21.3m in a Series B financing bringing its assets to a total of €50M. 

Read more